I-Mab
NASDAQ:IMAB
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
I-Mab
I-Mab operates as a clinical stage biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-01-17.
I-Mab operates as a clinical stage biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-01-17.
Revenue Drop: I-Mab reported revenue of $2.7 million in H1 2023, down from $7.7 million in H1 2022, mainly from collaborations with AbbVie and HI-Bio.
Strong Balance Sheet: The company ended June 30, 2023, with $414.6 million in cash, which management says is sufficient to fund strategic plans.
Strategic Refocus: I-Mab is prioritizing two oncology assets, uliledlimab and givastomig, for global development, and is shifting to become a US-based biotech company.
Positive Clinical Milestone: Eftansomatropin alfa, a long-acting human growth hormone, met its Phase 3 primary endpoint and showed non-inferiority to Norditropin, supporting plans for a 2024 BLA filing in China.
Cost Control: Both R&D and administrative expenses fell significantly year-over-year, reflecting ongoing streamlining.
Stock Buyback: The board authorized up to $40 million in share repurchases.
Upcoming Data Catalysts: Key readouts and regulatory submissions expected in 2024, including for lead assets in oncology and rare diseases.
